| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer
1 company
Hans Hull last filed a Form 4 in January 2025, as Chief Business Officer at PLRX. Hans Hull's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Hans Hull a strong insider score of 79/100, based on 8 past trades. Over a 12-month horizon, all 8 of those trades were profitable, with an average 12-month return of +44.2%.
At the last filing, the largest reported position was 251,708 shares of PLRX. The PLRX filings lean toward selling, a net 106,262 shares.
Hans Hull has 18 Form 4 filings on record from June 2020 to January 2025, all as Chief Business Officer at Pliant Therapeutics (PLRX), 2020–2025.
The 29 reported transactions were 9 open-market sales, 7 stock awards, 7 option or other derivative awards and 4 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 7 sales worth about $1.9M.
The largest open-market sale was 34,919 shares of PLRX at an average $20.01 on August 4, 2023, about $699K. Twelve months later PLRX was down 31%.
All 5 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
Shares as reported in the last Form 4 for each company; the most recent is from January 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2025 | PLRX Pliant Therapeutics, Inc. | Chief Business Officer | Sell10b5-1 | 15,936 | $11.20 | $178,500.73 | -7.0% | -87.0% | -88.5% | |
| Jul 10, 2024 | PLRX Pliant Therapeutics, Inc. | Chief Business Officer | Sell10b5-1 | 9,900 | $11.56 | $114,444.00 | -4.2% | +1.4% | -87.4% | |
| Jan 17, 2024 | PLRX Pliant Therapeutics, Inc. | Chief Business Officer | Sell10b5-1 | 9,786 | $17.23 | $168,612.78 | -5.0% | -25.7% | -35.0% | |
| Aug 4, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Business Officer | Sale+OE10b5-1 | 34,919 | $20.01 | $698,580.50 | -15.2% | -25.4% | -31.2% | |
| Jul 17, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Business Officer | Sell10b5-1 | 17,937 | $18.01 | $323,029.23 | -7.6% | -13.7% | -24.3% | |
| Mar 30, 2023 | PLRX Pliant Therapeutics, Inc. | Chief Business Officer | Sell10b5-1 | 9,036 | $26.52 | $239,642.85 | -4.3% | -28.3% | -43.9% | |
| Dec 20, 2022 | PLRX Pliant Therapeutics, Inc. | Chief Business Officer | Sell | 8,748 | $19.10 | $167,107.80 | -6.0% | +45.1% | -14.4% |